Tag: Abbvie

Recent product recalls and the discontinuation of some older product lines have led many consumers to question, "Are REFRESH eye drops being discontinued?" While some specific products, like certain lots of Refresh Relieva PF, have been affected by recalls or phased out, the overall REFRESH brand from manufacturer AbbVie is not being discontinued.

In recent years, several eye drop brands have been subject to recalls due to potential contamination or manufacturing concerns. Regarding the specific question, yes, certain Refresh brand eye drops and ointments have been recalled by the manufacturer, Allergan (a subsidiary of AbbVie).

In February 2022, the U.S. Food and Drug Administration (FDA) approved the first generic version of the dry eye medication, Restasis. This pivotal moment marked the end of decades of market exclusivity for the brand-name drug and profoundly impacted patient access and cost.

First approved by the FDA on March 5, 2020, Durysta marked a breakthrough in glaucoma treatment by offering a sustained-release implant alternative to daily eye drops. This article explores the precise timeline surrounding the question of **how long has Durysta been on the market** and its subsequent impact on ophthalmology.

Since the first U.S. biosimilar launch in January 2023, Humira's market has been completely reshaped [1.2.3, 1.6.4]. The introduction of over a dozen competing products is driving a major shift in treatment, so is Humira being phased out? While not discontinued, its dominance is rapidly declining.